InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Acute Vulvovaginal Candidiasis Market- by Drug Type (Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole and Other Drug Types), Route of Administration (Oral, Intravenous and Topical), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), Trends, Industry Competition Analysis, Revenue and Forecast To 2030.”
According to the latest research by InsightAce Analytic, the global Acute Vulvovaginal Candidiasis Market Size is valued at USD 339.50 Million in 2024 and is predicted to reach USD 507.32 Million by the year 2034 at a CAGR of 4.2% during the forecast period for 2025-2034.
Request For Free Sample Pages:
https://www.insightaceanalytic.com/request-sample/1232
The development of numerous treatments and medications to treat this infection is part of the acute vulvovaginal candidiasis market. A yeast infection known as acute vulvovaginal candidiasis (VVC) or vaginal thrush is brought on by the candida Albicans fungal group. Overgrowth of fungus, which results in symptoms including abnormal vaginal discharge, excruciating discomfort during sexual activity, and vaginal itching, causes the infection.
The population’s rising prevalence of acute vulvovaginal candidiasis will likely fuel global market growth over the predicted period. Accelerated R&D on VVC medicines and therapies will probably drive the worldwide acute vulvovaginal candidiasis market during the forecast period. There is a rush among market competitors to submit new drug applications (NDA) to regulatory authorities that will grant them approval to manufacture their products. This aspect is projected to drive the worldwide acute vulvovaginal candidiasis market forward.
North America is anticipated to be the major contributor to the Acute Vulvovaginal Candidiasis market over the forecast years because of the rising occurrence of acute vulvovaginal candidiasis therapy in this area. In terms of revenue, the United States dominates North America’s acute vulvovaginal candidiasis market. In addition, the Asia Pacific regional market is expected to register significant growth during the estimated period.
Curious about this latest version of the report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1232
Major market players operating in the Acute Vulvovaginal Candidiasis market include
Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Padagis LLC, ProFem GmbH, Amplyx Pharmaceuticals Inc., MethylGene Inc., Ferrer Internacional S.A., Pfizer, Inc., and Other Prominent Players.
Recent collaborations and agreements in the market:
- In February 2021, Scynexis, a biotech business, announced an agreement with Amplity Health, a pharmaceutical company, to extend their support for the commercialization of BrexafemmeTM, a brand name of Ibrexafungerp for vaginal infections, in the United States.
- In October 2019, Mycovia Pharmaceuticals, an American pharmaceutical business, announced a collaboration with Gedeon Richter, a Hungarian pharmaceutical company, to manufacture VT-1161 for the treatment of vulvovaginal candidiasis.
Get Specific Chapter/Information From The Report:@
https://www.insightaceanalytic.com/customisation/1232
Market Segments
Global Acute Vulvovaginal Candidiasis Market, by Drug Type, 2025-2034 (Value US$ Mn)
- Clotrimazole
- Nystatin
- Fluconazole
- Ketoconazole
- Terbinafine
- Terconazole
- Other Drug Types
Global Acute Vulvovaginal Candidiasis Market, by Route of Administration, 2025-2034 (Value US$ Mn)
- Oral
- Intravenous
- Topical
Global Acute Vulvovaginal Candidiasis Market, by Distribution Channel, 2025-2034 (Value US$ Mn)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Acute Vulvovaginal Candidiasis Market, by Region, 2025-2034 (Value US$ Mn)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
North America Acute Vulvovaginal Candidiasis Market, by Country, 2025-2034 (Value US$ Mn)
- S.
- Canada
Europe Acute Vulvovaginal Candidiasis Market, by Country, 2025-2034 (Value US$ Mn)
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific Acute Vulvovaginal Candidiasis Market, by Country, 2025-2034 (Value US$ Mn)
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America Acute Vulvovaginal Candidiasis Market, by Country, 2025-2034 (Value US$ Mn)
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa Acute Vulvovaginal Candidiasis Market, by Country, 2025-2034 (Value US$ Mn)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Get More Inforamtion :
https://www.insightaceanalytic.com/report/-acute-vulvovaginal-candidiasis-market-/1232
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.
Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
